TOKYO – If you’re wondering why South Korea’s economy is outperforming Japan’s in 2021 by such a wide margin, events at drugmaker Celltrion offer some timely clues.
On Monday, the Incheon-based biopharmaceutical outfit announced positive results for an experimental antibody Covid-19 treatment. Clinical trials indicate it reduces the treatment period by nearly five days in Phase 3 global clinical trials.
The breakthrough is a reminder of how neighboring, more developed Japan is conspicuously absent from the vaccinations and therapeutics conversation.
